CORRECTION - 23andMe to Report Q2 FY2025 Financial Results
23andMe (Nasdaq: ME) has announced a correction to its earlier release regarding the timing of its Q2 FY2025 financial results report. The company will now release results before the market opens on Tuesday, November 12, 2024, rather than after market close as previously stated. A conference call will be held at 8:00 a.m. Eastern Time the same day. Shareholders can submit questions through the Say Technologies platform up until 24 business hours before the call.
23andMe (Nasdaq: ME) ha annunciato una correzione al suo precedente comunicato riguardo al momento della pubblicazione del report finanziario del secondo trimestre dell'anno fiscale 2025. L'azienda rilascerà ora i risultati prima dell'apertura del mercato martedì 12 novembre 2024, anziché dopo la chiusura del mercato come dichiarato in precedenza. Una conference call si terrà alle 8:00 a.m. Eastern Time lo stesso giorno. Gli azionisti possono inviare domande tramite la piattaforma Say Technologies fino a 24 ore lavorative prima della chiamata.
23andMe (Nasdaq: ME) ha anunciado una corrección a su comunicado anterior sobre el momento de su informe de resultados financieros del segundo trimestre del año fiscal 2025. La empresa publicará ahora los resultados antes de la apertura del mercado el martes 12 de noviembre de 2024, en lugar de después del cierre del mercado como se había indicado anteriormente. Se llevará a cabo una llamada de conferencia a las 8:00 a.m. Eastern Time el mismo día. Los accionistas pueden enviar preguntas a través de la plataforma Say Technologies hasta 24 horas hábiles antes de la llamada.
23andMe (Nasdaq: ME)는 2025 회계연도 2분기 재무 결과 보고서의 발표 시기에 대한 이전 발표의 수정 사항을 발표했습니다. 이제 이 회사는 2024년 11월 12일 화요일 시장 개장 전에 결과를 발표할 것이며, 이전에 언급한 시장 마감 후가 아닙니다. 같은 날 동부 표준시 기준 오전 8시에 컨퍼런스 콜이 열릴 예정입니다. 주주들은 전화 회의 24시간 전까지 Say Technologies 플랫폼을 통해 질문을 제출할 수 있습니다.
23andMe (Nasdaq: ME) a annoncé une correction à son précédent communiqué concernant le calendrier de son rapport de résultats financiers pour le deuxième trimestre de l'exercice 2025. L'entreprise publiera désormais les résultats avant l'ouverture du marché le mardi 12 novembre 2024, plutôt qu'après la fermeture du marché comme indiqué précédemment. Une conférence téléphonique aura lieu le même jour à 8h00, heure de l'Est. Les actionnaires peuvent soumettre des questions via la plateforme Say Technologies jusqu'à 24 heures ouvrables avant l'appel.
23andMe (Nasdaq: ME) hat eine Korrektur zu seiner vorherigen Mitteilung hinsichtlich des Zeitpunkts des Berichts über die finanziellen Ergebnisse des 2. Quartals des Geschäftsjahres 2025 angekündigt. Das Unternehmen wird die Ergebnisse vor Markteröffnung am Dienstag, den 12. November 2024, veröffentlichen, anstatt wie zuvor angegeben nach Marktschluss. Am selben Tag wird um 8:00 Uhr Eastern Time eine Telefonkonferenz stattfinden. Aktionäre können bis zu 24 Betriebsstunden vor dem Anruf Fragen über die Plattform Say Technologies einreichen.
- None.
- None.
SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- An earlier release under the same headline should have noted 23andMe Holding Co. (Nasdaq: ME) (23andMe) will report financial results for the second quarter of fiscal year 2025 (FY2025) prior to the market opening on Tuesday, November 12, 2024 (the prior release incorrectly stated the results would be reported after the market closes). The Company will webcast a conference call at 8:00 a.m. Eastern Time on that date to discuss the quarter’s results and report on business progress.
The webcast can be accessed on the day of the event at this link. A webcast replay will be available at the same address following the event. In addition, 23andMe will use the Say Technologies platform to allow retail and institutional shareholders to submit and upvote questions to management in advance of the earnings conference call. Shareholders can submit questions by visiting this link. The Q&A platform will remain open until 24 business hours before the earnings call.
About 23andMe
23andMe is a genetics-led consumer healthcare and therapeutics company empowering a healthier future. For more information, please visit investors.23andme.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the future performance of 23andMe’s businesses in consumer genetics and therapeutics and the growth and potential of its proprietary research platform. All statements, other than statements of historical fact, included or incorporated in this press release, including statements regarding 23andMe’s strategy, financial position, financial projections, funding for continued operations, cash reserves, projected costs, database growth, plans, and objectives of management, are forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," “predicts,” "continue," "will," “schedule,” and "would" or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on 23andMe’s current expectations and projections about future events and various assumptions. 23andMe cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe’s forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, and as revised and updated by our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The statements made herein are made as of the date of this press release and, except as may be required by law, 23andMe undertakes no obligation to update them, whether as a result of new information, developments, or otherwise.
Contacts
Investor Relations Contact: investors@23andme.com
Media Contact: press@23andMe.com
FAQ
When will 23andMe (ME) release Q2 FY2025 earnings?
What time is 23andMe's (ME) Q2 FY2025 earnings call?
How can shareholders submit questions for 23andMe's (ME) Q2 earnings call?
